David Earl, MD
Psychiatry · Albuquerque, NMNPI 1306113246
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.2% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,339, 6.0 times the $224 reported in 2020. Among psychiatry clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 31 payments — averaging $87.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avadel CNS Pharmaceuticals, LLC$541
- Jazz Pharmaceuticals Inc.$241
- Teva Pharmaceuticals USA, Inc.$240
- Alkermes, Inc.$223
- AbbVie$216
- Harmony Biosciences LLC$173
- plus $1K from 12 others
What the payments were for
- Consulting fees$1506%
- Food & beverage$2,45090%
- Education$1164%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMRYZ$541
- ARISTADA$485
- LYBALVI$409
- REXULTI$266
- XYWAV$150
- XYREM$150
- INVEGA SUSTENNA$125
- GVOKE PFS$124
- NURTEC ODT$122
- ARISTADA INITIO$121
- AUSTEDO$115
- Inspire$114
How this compares
$2,716 in reported general payments places this provider in the 90th percentile of 174 psychiatry providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelsomraSuvorexant | 41 | $23,127 |
| Varenicline Tartrate | 11 | $2,087 |
| Pregabalin | 29 | $1,013 |
| Gabapentin | 46 | $609 |
| Ropinirole Hcl | 21 | $605 |
| Ramelteon | 11 | $535 |
| Modafinil | 12 | $398 |
| Clonazepam | 24 | $289 |
| Doxepin Hcl | 32 | $251 |
| Famotidine | 18 | $201 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 13 | $197 |
| Zolpidem Tartrate ErZolpidem Tartrate | 12 | $101 |
| Topiramate | 12 | $54 |
| Alprazolam | 14 | $46 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Albuquerque
- Patricio EscalonaAlbuquerque$487K
- Mauricio TohenAlbuquerque$160K
- Shiva SharmaAlbuquerque$140K
- Javier VeraAlbuquerque$8K
- Nancy MartinAlbuquerque$6K
- Reuben SutterAlbuquerque$5K
- Swala AbramsAlbuquerque$3K
- Ronald RomanikAlbuquerque$2K
- Anthony HolzgangAlbuquerque$2K
- Mahvish KhanAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.